Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 258.36M |
| Revenue (ttm) | 5.23M |
| Net Income (ttm) | -216.39M |
| Shares Out | 361.49M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,507,525 |
| Open | 0.730 |
| Previous Close | 0.724 |
| Day's Range | 0.702 - 0.760 |
| 52-Week Range | 0.620 - 3.730 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 6.00 (+739.51%) |
| Earnings Date | Nov 12, 2024 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. ... [Read more]
Financial Performance
In 2023, Lexicon Pharmaceuticals's revenue was $1.20 million, an increase of 766.19% compared to the previous year's $139,000. Losses were -$177.12 million, 73.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price forecast is $6.0, which is an increase of 739.51% from the latest price.
News
US FDA declines to approve Lexicon Pharma's add-on diabetes drug
The U.S. Food and Drug Administration declined to approve Lexicon Pharmaceuticals' add-on drug for type 1 diabetes and chronic kidney disease, the company said on Friday.
Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
THE WOODLANDS, Texas, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it has received a complete response letter (CRL) from the U.S. Food and Drug Admini...
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Strong Interest in Trial Participation Resulted in Enrollment Exceeding Target by 20 Percent and Completion Ahead of Schedule
Lexicon Pharmaceuticals to Participate in December Investor Conferences
THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon's chief executive officer an...
Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development
Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, effective Dec. 31, to eliminate commercial activities and focus on drug development.
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions
Lexicon Appoints Ivan H. Cheung to Board of Directors
THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors.
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript
Start Time: 17:00 January 1, 0000 5:55 PM ET Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call November 12, 2024, 17:00 PM ET Company Participants Mike Exton - CEO and Director Tom Ga...
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference. Lexicon man...
Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease
People with T1D and CKD treated with sotagliflozin and insulin had similar lowering effects on glycated hemoglobin (HbA1c), the primary endpoint, as people with T1D who do not have CKD
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease
THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug Administration (FDA) Endocrinologic and Metab...
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' add-on treatment to insulin therapy for managing blood glucose levels in a...
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
-Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone payments -Lexicon to receive an upfront payment of $25 million and the potent...
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
Continues to Expand Viatris' Innovative Portfolio in Cardiovascular Diseases Leverages Viatris' Unique Global Infrastructure and Expertise Includes Opportunities to Leverage the Potential of Sotaglifl...
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon's novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step down to...
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences tak...
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 2024 Annual Conference...
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and ca...
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2024 Earnings Call Transcript
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Lisa DeFrancesco – Head-Investor Relations and Corporate Strategy Mike Exto...
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the market...
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief execu...